Research Advancements of Antibody-Drug Conjugates in Breast Cancer at 2024 ASCO Annual Meeting

VernacularTitle:2024 ASCO会议抗体偶联药物在乳腺癌中的研究进展
Author: Hunan YE ¹ ; Yulan SHEN ; Jiaying LI ; Huanhuan ZHOU ; Fanrong ZHANG ; Xiaojia WANG
Author Information

1. 310053 杭州,浙江中医药大学第二临床医学院
Publication Type:Journal Article
Keywords: Breast cancer; Antibody-drug conjugates; ASCO; 2024
From: Cancer Research on Prevention and Treatment 2025;52(3):185-192
CountryChina
Language:Chinese
Abstract: The 2024 American Society of Clinical Oncology(ASCO)Annual Meeting was held in Chicago,the United States,from May 31 to June 4 in 2024.In recent years,antibody-drug conjugates(ADCs)have become one of the most popular targeted therapies because of their high specificity,efficacy,and low toxicity,making them a focal point in this ASCO meeting.Currently,over 100 ADCs are under investigation,demonstrating the considerable development potential of ADCs in the field of targeted cancer therapy.The aforementioned conference reported several recent research advancements regarding ADCs for the treatment of breast cancer(BC).This review summarizes the latest progress of ADCs in BC treatment discussed at the confer-ence.